Morote J, Cozar JM, Durán I, Gómez F, León L, Maroto P, Miñana B, Solsona E, Oyagüez I, Casado MA, Roldán C, Gutierrez L, Hechmati G
Cost assessment of metastatic and non-metastatic castration-resistante prostate cancer patient-management in Spain
16th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Dublin, Irlanda. 2-6 nov 2013
Torres C, Betoret I, Sabater E, Riera M, Casado MA, Figueras M
Cost-effectiveness analysis of glycopyrronium bromide in the treatment of chronic obstructive pulmonary disease in Spain
16th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Dublin, Irlanda. 2-6 nov 2013
Ariza-Ariza R, Van Walsem A, Canal C, Roldán C, Betegón L, Oyagüez I, Janssen K
Cost-minimization analysis of subctuaneous abatacept in the treatment of rheumatoid arthritis in Spain
16th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Dublin, Irlanda. 2-6 nov 2013
Menéndez R, Rodríguez-GonzálezMoro JM, Gros B, Echave M, Oyagüez I, Lwoff N, Egea-García M, Guijarro P
Cost-effectiveness of a 13-valent conjugate pneumococcal vaccination program in COPD patients aged ≥50 years in Spain: Preliminary results
16th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Dublin, Irlanda. 2-6 nov 2013
XLIII Congreso Sociedade Galega de Reumatoloxía. Evaluación Económica de Intervenciones Sanitarias en Reumatología: Terapias Biológicas. ¿Qué debo saber para no morir en el intento?
Noviembre 2013. A Coruña
Álvarez-Sabín J, Masjuan J, Casado MA, Mar J, Oliva J, González-Rojas N
Costs in patients along first year poststroke in Spain
16th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Dublin, Irlanda. 2-6 nov 2013
Álvarez-Sabín J, Masjuan J, Yébenes M, Mar J, Oliva J, González-Rojas N
Disease burden of ischemic stroke along first year post-stroke in Spain
16th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Dublin, Irlanda. 2-6 nov 2013
Turnes J, Oyagüez I, Planas R, García-Samaniego J, Diago M, Crespo J, Calleja JL, Solà R, Casado MA, Romero-Gómez M
Cost-saving approach to triple therapy for hepatitis C using the OPTIM prognostic tool to predict virologic response to 4 weeks of peginterferon and ribavirin in genotype 1 patients
The Liver Meeting, AASLD’s 64th Annual Meeting in Washington, EEUU, 1-5 Noviembre 2013
Buti M, Gros B, Oyagüez I, Andrade RJ, Serra MA, Turnes J, Casado MA
Cost-effectiveness analysis of telaprevir triple therapy for treatment-naïve patients with chronic hepatitis C based on the combined efficacy of the ADVANCE and OPTIMIZE studies
The Liver Meeting, AASLD’s 64th Annual Meeting in Washington, EEUU, 1-5 Noviembre 2013
Pàmpols Felip M, Frias López C, Torres González C, Pericay Pijaume C, Oyagüez Martín I, Casado Gómez MA